Page1

Technology/ Title	DBPR117/ A mAb Targeting RSPO3/Wnt- For Cancer Treatment		
Subtitle			
Technology Type	☐Biotechnology		☐Device/Diagnostics
	■Pharmaceutical		☐Others:_____
Contact Person	Name: Cindy Hsieh		Title: Manager
	Telephone(work): +886-37246166-33209		Mobile:
	Email: wenchuan@nhri.edu.tw		
Link	http://ibpr.nhri.org.tw/zhtw/wp-content/uploads/2018/07/New-2018_NCR-of-DBPR117.pdf		
Technology Description	R-spondin 3 (RSPO3) was identified as a novel key modulator of cancer development and a potential target for treatment of cancers. Therefore, we selected RSPO3 as a therapeutic target and discovered a potent neutralizing antibody, DBPR117, that was shown to have anti-cancer activity. DBPR117 is a humanized IgG1 that is capable of neutralizing the aberration of RSPO3-mediated Wnt/β-catenin signaling. DBPR117 is comparable with rosmantuzumab (131R010), an antibody developed by OncoMed, as shown in a number of assays including binding assays, *in vitro* ligand neutralization and wound healing assays, and *in vivo* PDX (patient-derived xenograft) or CDX (cell line-derived xenograft) models.		

Page2

Intellectual Property	Patent title: Anti-RSPO3 antibodies, compositions, methods and uses Approval: USA (US11623951B2), Japan (JP7370997), Taiwan (I 702050), China (ZL201880079067.5)
Key Publications	N/A
Business Opportunity	DBPR117 can inhibit cancer stemness and DBPR117 will be examined for activity in reducing RSPO3-mediated tumorigenesis and metastasis. DBPR117 will be developed to cover a wide range of cancers along with companion diagnostics that can identify patients who are most likely to benefit from DBPR117, alone or in combination with other agents.

Cancer cell (without RSPO3 ab)　　**Cancer cell (with DBPR117 RSPO3 ab)**